Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The company's vaccines are administered using convenient room temperature-stable tablets that can be stored and shipped without refrigeration and eliminate risk of needle-stick injury. Its development programs are oral tablet vaccines designed to protect against norovirus, seasonal influenza and respiratory syncytial virus, as well as a therapeutic vaccine for human papillomavirus. Vaxart, Inc., formerly known as Aviragen Therapeutics, is based in South San Francisco, United States.
| Revenue (Most Recent Fiscal Year) | $237.26M |
| Net Income (Most Recent Fiscal Year) | $16.33M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | 12.50 |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.76 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.05 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 7.32 |
| Pre-Tax Margin (Trailing 12 Months) | 7.08% |
| Net Margin (Trailing 12 Months) | 6.88% |
| Return on Equity (Trailing 12 Months) | 33.83% |
| Return on Assets (Trailing 12 Months) | 9.10% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.57 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.57 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.37 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.24 |
| Earnings per Share (Most Recent Fiscal Year) | $0.07 |
| Diluted Earnings per Share (Trailing 12 Months) | $0.06 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 241.41M |
| Free Float | 234.65M |
| Market Capitalization | $181.06M |
| Average Volume (Last 20 Days) | 0.38M |
| Beta (Past 60 Months) | 1.31 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 2.80% |
| Percentage Held By Institutions (Latest 13F Reports) | 18.05% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |